Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nedocromil sodium is a non-steroidal prophylactic agent for the management of asthma. We assessed the effect of inhaled of nedocromil sodium 8 mg/24 h in a double blind, placebo controlled study in 14 patients suffering from seasonal (grass-pollen) asthma. Symptom scores for dyspnoe, cough, rhinitis and airway responsiveness to histamine (PC20H) according to Cockcroft et al were estimated before the grass-pollen season and at the end of 14-day placebo treatment and 21-day nedocromil sodium treatment. During placebo period the significant decrease in PC20H from 1.81 mg/ml to 0.54 mg/ml (p < 0.01) was observed. Nedocromil sodium did not have the effect on nonspecific bronchial responsiveness, PC20 - 0.74 mg/ml (p = 0.25). Subjective global assessment scores were significantly better with nedocromil sodium (31.15 mean 2.23) than with placebo (10.5 mean 0.7) p < 0.05.
Pneumonol Alergol Pol 1995
PMID:[Effect of nedocromil sodium on clinical course and histamine airway responsiveness in patients with pollen induced bronchial asthma]. 764 32

The examinations of the external auditory canals among the group of 53 asymptomatic (before the season) grass pollen sensitive patients have been performed by means of fiberoptic otoscope. The mechanical irritation of the walls of the auditory canals resulted in the cough reflex in 11 patients. The analysis of the lack or presence of any bronchial symptoms (during or out of the season) among the whole group has been made. The conclusion was, that oto-respiratory (or oto-cough) reflex may be the predictive measure of any bronchial symptoms among pollinosis patients. In the aspect, the sensitivity of the was 50%, but its specificity--92%.
Pol Tyg Lek
PMID:[Oto-respiratory reflex in patients with pollinosis]. 785 90

The examination were carried out in a group of 14 patients with mild bronchial asthma. The effect of Berodual (1 dose = 0.02 mg ipratropium bromide + 0.05 mg fenoterol), ipratropium bromide (Atrovent, 1 dose = 0.02 mg) and fenoterol (Berotec, 1 dose = 0.2 mg) were assessed. All the drugs were administered 3 x 2 doses/daily, except Berotec--3 x 1 dose/daily--during 14 days. Dyspnoea, cough, sputum scores were calculated and values of FEV1, FVC, FEF25-75 and PC20 (mg/ml metacholine) were measured. All this drugs after 2 weeks therapy statistically significantly reduced dyspnoea, cough and sputum. The best bronchodilating and protective effect were observed after Berodual compare with Atrovent or Berotec.
Pneumonol Alergol Pol 1994
PMID:[Effect of fenoterol, ipratropium bromide and combination drug-berodual-on selected clinical parameters and lung function in patients with asthma]. 795 Oct 83

Asthma is one of the most common chronic diseases of childhood. Its clinical manifestation is not as typical as adult asthma. Recurrent episodes of cough and wheezing are the most frequent symptoms. There is no universally accepted definition of childhood asthma. Asthma is more likely to be missed or labelled as bronchitis. Underdiagnosis causes the delay in regular and specific treatment.
Pneumonol Alergol Pol 1994
PMID:[Bronchial asthma as a disease seldom recognized in children]. 795 Oct 94

Study was designed to investigate the effect of prolonged application of captopril on pulmonary ventilation in patients with chronic congestive heart failure (CCHF) without hypertension. Studies were carried out in 13 men aged 54-65 yrs with CCHF due to ischaemic heart disease. They were classified hemodynamically as III or IV stage according to the NYHA classification. Two periods of management were investigated. In the 1st period, lasting at least one month, cardiac glycosides, diuretics, nitrates, as well as diet and restricted physical activity were applied. In the 2nd period, lasting 21 days, additionally captopril was given in a daily dose of 2 x 12.5 or 2 x 25 mg depending on the drug tolerance. When the periods were terminated pulmonary ventilation was measured. The following indices were determined: FEF25, FEF50, FEF75, FEF25-75, FEV1, FVC,FEV1/FVC, SVC, FIVC, FIF25, FIF50, FIF75, FIF25-75. No significant effect of captopril upon pulmonary ventilation was found (p < 0.05). In any of the patients captopril-induced cough was not observed. It is concluded that prolonged management with captopril in patients with CCHF without hypertension has no disadvantageous influence upon pulmonary ventilation with exception of patients who are hypersensitive to the drug.
Pol Arch Med Wewn 1994 Feb
PMID:[Influence of prolonged application of captopril upon pulmonary ventilation in patients with chronic congestive heart failure]. 800 21

The effect of 12 weeks therapy with nedocromil sodium given as MDI-aerosol, 8 mg/daily in a group of 20 atopic asthmatic patients was studied. The selected spirometric parameters (PEF, FEV1, FVC, FEF25-75%, Raw) and clinical symptoms of bronchial asthma (dyspnoea, cough, sputum) were assessed. Additionally the percentage reduction of bronchodilators usage was obtained. A significant improvement was observed in spirometric parameters. A statistically significant reduction in clinical symptoms of bronchial asthma and bronchodilators usage was noted.
Pneumonol Alergol Pol 1993
PMID:[Analysis of selected spirometric parameters and results of therapy with nedocromil sodium in patients with asthma]. 840 44

An effect of a 6-week therapy with Budesonide forte aerosol Polfa on the course of bronchial asthma has been investigated in 30 atopic asthmatics with double-blind trial. The drug has been administrated in the dose of 200 micrograms four times daily and the results have been compared with placebo and foreign made analogue. Twelve patients required chronic administration of oral glucocorticosteroids in the daily dose of 9.2 mg of prednisone. Dyspnoea, cough, doses of bronchodilators and oral corticosteroids, pulmonary function and bronchial reactivity to histamine have been considered in the clinical analysis. A decrease in the severity of dyspnoea and in the doses of used bronchodilators as well as intensity of cough have been observed during the treatment with inhaled steroids. The mean daily dose of prednisone has decreased to 5.8 mg and oral corticosteroids could be withdrawn in 4 of the patients treated chronically with these drugs. Budesonide forte significantly reduced bronchoconstriction and bronchial reactivity to histamine, compared with baseline values.
Pol Tyg Lek
PMID:[Clinical evaluation of budesonide forte action in patients with atopic bronchial asthma]. 841 65

Headache with paroxysmal vertigo were induced by cough in a case of the Arnold-Chiari type I malformation. The authors suggest that exertional headache and posterior cranial fossa symptoms of unclear aetiology may indicate presence of the syndrome, and the availability of magnetic resonance imaging made possible the detection of the malformation.
Neurol Neurochir Pol
PMID:[Cough headache and vertigo as symptoms of the Arnold-Chiari syndrome]. 850 49

The medical-environmental questionnaire, physical examination and pre-shift and post-shift spirometry have been performed in 48 furniture factory workers. The workers showed the work-related symptoms: cough, shortness of breath, chest pain, headache, general malaise, skin symptoms, eye symptoms, rhinitis. No relationship was found between the spirometry values and the frequency of the symptoms. The exposed workers showed a significant post-shift reduction of the FVC, FEV1, FEV1%VC and PEF (p < 0.001). The higher drops of the spirometric parameters occurred in younger workers. The presented data show that processing of wood may be associated with the work-related respiratory symptoms and diseases in exposed workers.
Pneumonol Alergol Pol 1996
PMID:[The effect of wood dust on the respiratory system. Medical examination of furniture factory workers]. 919 Feb 35

This study was designed to examine the efficacy and tolerability of ambroxol (Ambrosol) on the symptomatology of chronic bronchitis among in- and out-patients. Seventy patients were included in the trial and divided into two random groups. The patients were treated in a double-blind way with either Ambrosol or a placebo for 2 months. The physician and the patient assessed the following points: the feeling general well-being, the symptoms of a cold and of fever, the need for treatment with antibiotics, the amount, viscosity and colour of sputurn, the difficulty in expectoration, the severity of coughing and any changes in breathlessness while at rest. In order to carry out these subjective assessments we used a scoring system. We observed that, breathlessness while at rest and the rate of exacerbation was significantly lower in the Ambrosol group after 2 weeks of therapy. Sputum viscosity, difficulty in expectoration and severity of coughing were reduced in this group after 4 or 8 weeks. Throughout the 2-month period of therapy, the tolerability of ambroxol was good. A total of 4 patients reported side-effects of various degrees of severity. One patient stopped the therapy due to these side-effects (dizziness). There was no significant difference in the number of side-effects between the two groups (Ambrosol vs Placebo).
Pneumonol Alergol Pol 1996
PMID:[Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis]. 919 Feb 45


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>